TCR-T cell therapy for AFP-positive liver and other cancers
Part of Cancer, Digestive system clinical trials.
This trial tests an experimental cell treatment called HRYZ-T102 TCR-T for people with advanced liver cancer or other solid tumors that make a protein called AFP. The treatment uses your own immune cells, modified in a lab to target and kill cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cancer (like liver cancer) that produces a protein called AFP.
- You must carry a specific gene type called HLA-A*02:03 (a blood test can check).
- You must have tried at least one standard treatment and it didn't work or you couldn't continue.
- Your cancer must be advanced (spread or cannot be removed by surgery) and your liver score (Child-Pugh) must be 7 or less.
- You must be in good enough health to take care of yourself (ECOG score 0 or 1) and have normal blood counts and organ function.
- You cannot have certain other serious health problems like active infections, recent bleeding, or a history of certain heart or immune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (multi-target Hi-TCR-T cells) for people with advanced liver cancer that hasn't responded to earlier treatments. The therapy targets several markers on your cancer cells to try to attack the tumor more effectively.
This trial tests a new treatment called CNCT19, which uses your own immune cells to fight liver cancer. It's for people with advanced liver cancer that hasn't responded to standard treatments or can't be treated with surgery or local procedures.
This trial tests an experimental cell therapy for people with advanced solid tumors that have not responded to standard treatments. It targets tumors with specific genetic markers (KRAS or NRAS G12D and HLA-A*11:01) to see if it can shrink or slow the cancer.
This trial tests a new type of immune cell therapy, called CAR-T cells, that are engineered to target a protein called GPC3 found on liver cancer cells. It is for people with advanced liver cancer that has not responded to previous treatments.
This trial tests a personalized treatment using your own immune cells (T-cells) trained to attack specific markers on your liver cancer. It is for people with advanced liver cancer that has worsened after at least two prior treatments and who have tumor tissue available for genetic testing.
This study tests a new cell therapy (called CG-102-12C) for advanced liver cancer that has a specific marker (GPC3) and has stopped responding to standard treatments. The therapy uses your own immune cells, specially trained to attack the cancer. This might be an option if you have tried other treatments and they no longer work or cause bad side effects.
Hear when a new Hepatic Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.